Viatris | VTRS - Assets


Viatris reported $34.68B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Celltrion KRW 779.18B 10.37B Jun/2026
Cspc Pharmaceutical CNY 46.7B 695.56M Dec/2025
Deva Holding AS TRY 12.93B 1.83B Sep/2023
Dianthus Therapeutics USD 1.28B 62.98M Sep/2026
Divis Laboratories Ltd INR 219.64B 19.31B Sep/2026
Kangmei Pharma CNY 13.07B 239.31M Jun/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Laboratorios Farma EUR 799.88M 99.95M Dec/2023
Malin Corporation EUR 198.5M 70.1M Dec/2024
Medical Developments International AUD 63.57M 2.83M Dec/2025
Neuren Pharmaceuticals AUD 342.86M 11.61M Dec/2025
Organigram Holdings CAD 820.26M 298.95M Jun/2026
Ovoca Bio EUR 2.07M 414K Dec/2025
Pharma Mar EUR 408.4M 14.8M Sep/2026
Qiagen NV USD 5.89B 107.14M Jun/2026
Sartorius EUR 9.67B 70.9M Sep/2026
Sino Biopharmaceutical CNY 74.89B 9.49B Jun/2025
Tilray USD 2.1B 15.95M Sep/2025
Viatris USD 34.68B 362M Sep/2026
Zealand Pharma A/S 15.3B 647.8M Mar/2026
Zz Pientze Pharmaceu CNY 17.71B 799.05M Sep/2026